A Study of Trilaciclib Combined With mFOLFIRINOX in the Treatment of Patients With Advanced Pancreatic Cancer
Status:
Recruiting
Trial end date:
2026-10-28
Target enrollment:
Participant gender:
Summary
To observe the incidence of chemotherapy-induced myelosuppression and the safety of
Trilaciclib combined with mFOLFIRINOX in patients with advanced pancreatic cancer receiving
first-line treatment.
Phase:
Phase 2
Details
Lead Sponsor:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School